1. “Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease”
by Caitlin V. M. L. Jie, Valerie Treyer, Roger Schibli and Linjing Mu
Pharmaceuticals 2021, 14(2), 110; https://doi.org/10.3390/ph14020110
Available online: https://www.mdpi.com/1424-8247/14/2/110
2. “Alpha-Synuclein PET Tracer Development—An Overview about Current Efforts”
by Špela Korat, Natasha Shalina Rajani Bidesi, Federica Bonanno, Adriana Di Nanni, Anh Nguyên Nhât Hoàng, Kristina Herfert, Andreas Maurer, Umberto Maria Battisti, Gregory David Bowden, David Thonon et al.
Pharmaceuticals 2021, 14(9), 847; https://doi.org/10.3390/ph14090847
Available online: https://www.mdpi.com/1424-8247/14/9/847
3. “[68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer”
by Ute Hennrich and Matthias Eder
Pharmaceuticals 2021, 14(8), 713; https://doi.org/10.3390/ph14080713
Available online: https://www.mdpi.com/1424-8247/14/8/713
4. “Development of 18F-Labeled Bispyridyl Tetrazines for In Vivo Pretargeted PET Imaging”
by Rocío García-Vázquez, Jesper Tranekjær Jørgensen, Klas Erik Bratteby, Vladimir Shalgunov, Lars Hvass, Matthias M. Herth, Andreas Kjær and Umberto Maria Battisti
Pharmaceuticals 2022, 15(2), 245; https://doi.org/10.3390/ph15020245
Available online: https://www.mdpi.com/1424-8247/15/2/245
5. “E-Cigarette Aerosol Deposition and Disposition of [11C]Nicotine Using Positron Emission Tomography: A Comparison of Nicotine Uptake in Lungs and Brain Using Two Different Nicotine Formulations”
by Anders Wall, Sara Roslin, Beatrice Borg, Simon McDermott, Tanvir Walele, Thomas Nahde, Grant O’Connell, Joseph Thompson, Mark Lubberink and Gunnar Antoni
Pharmaceuticals 2022, 15(3), 367; https://doi.org/10.3390/ph15030367
Available online: https://www.mdpi.com/1424-8247/15/3/367
